Research Report

Malignant Insulinoma  

Said Azzoug , Fadila Chabour , Leyla Rabehi , Farida Chentli
Department of Endocrine and Metabolic diseases, Bab El Oued Hospital, Algiers, Algeria
Author    Correspondence author
International Journal of Clinical Case Reports, 2015, Vol. 5, No. 10   doi: 10.5376/ijccr.2015.05.00010
Received: 17 Dec., 2014    Accepted: 17 Jan., 2015    Published: 27 Feb., 2015
© 2015 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:

Azzoug et al., 2015, Malignant insulinoma, International Journal of Clinical Case Reports, Vol.5, No. 10 1-3 (doi: 10.5376/ijccr.2015.05.0010)

Abstract

Malignant insulinomas are rare representing 4-14% of insulinomas with poor prognosis. Diagnosis of malignancy relies on the presence of lymph node or distant metastasis. Clinical manifestations of malignant insulinomas are similar but are more severe and frequent to those of benign insulinomas characterized by clinical hypoglycemic signs with predominance of neuroglucopenic symptoms. Surgical removal of the tumor and eventually metastasis is the corn stone of the treatment, other therapeutic modalities and anti-secretion drugs are complementary treatments. In this study we report the observations of three malignant insulinomas.  

 

Keywords
Malignant insulinoma; Hypoglycemia; Surgery; Anti-secretion drugs
[Full-Text PDF] [Full-Text HTML]
International Journal of Clinical Case Reports
• Volume 5
View Options
. PDF(170KB)
. HTML
Associated material
. Readers' comments
Other articles by authors
pornliz suckporn sex videos bbw mom xxx big fucking arabin porn videos teen gril sex video riding hard cock woman hard vagina . Said Azzoug
. Fadila Chabour
. Leyla Rabehi
. Farida Chentli
Related articles
. Malignant insulinoma
. Hypoglycemia
. Surgery
. Anti-secretion drugs
Tools
. Email to a friend
. Post a comment